AI Monitoring for T Cell Therapy Adverse Event Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing platforms for monitoring engineered T cell therapies, such as CAR T cells, lack real-time predictive analytics to anticipate and mitigate adverse events like Cytokine Release Syndrome (CRS) and Tumor Lysis Syndrome (TLS), due to their inability to integrate and analyze diverse, high-frequency data streams from patient monitoring systems, laboratory tests, imaging studies, and genomic profiles.
Innovation Solution
An AI-driven platform that integrates and processes real-time data from patient monitoring systems, laboratory tests, imaging studies, and genomic profiles, using advanced machine learning and deep learning algorithms to predict adverse events and provide personalized therapeutic recommendations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing monitoring platforms are used for engineered T cell therapies, then basic monitoring functionality is provided, but real-time predictive analytics capability is lacking
Solution Approach 1:
The patent combines multiple data sources (patient monitoring systems, laboratory tests, imaging studies, genomic profiles) and analytical capabilities (machine learning, deep learning, natural language processing) into a unified AI-driven platform. This integration enables real-time predictive analytics for adverse events while maintaining a cohesive system architecture that manages complexity through consolidation of previously separate monitoring functions.
Solution Approach 2:
The patent introduces an AI processing layer that acts as an intermediary between raw multi-modal data streams and clinical decision-making. This intermediary layer performs real-time data integration, pattern recognition, and predictive analysis, transforming complex raw data into actionable insights about adverse events like CRS and TLS, thereby enabling predictive analytics without directly exposing system complexity to end users.
2Measurement precision
If real-time data from multiple sources is integrated, then predictive analytics accuracy is improved, but data processing complexity increases
Solution Approach 1:
The patent segments the data integration process into distinct modular components that handle specific data types (vital signs, laboratory values, imaging data, genomic information). Each module processes its designated data stream independently using specialized algorithms, then integrates results at a higher level. This segmentation enables accurate multi-source data processing while managing complexity through modular architecture and clear separation of concerns.
3Reliability
If continuous monitoring is implemented, then adverse event detection capability is improved, but computational resource consumption increases
Solution Approach 1:
The patent implements periodic analysis cycles where the AI system continuously monitors data streams but performs comprehensive predictive analytics at optimized intervals rather than processing every data point in real-time. The system adjusts analysis frequency based on patient risk stratification and clinical context, performing intensive analysis when adverse events are more likely and reducing computational load during stable periods, thereby maintaining detection capability while managing resource consumption.
Data Source
AI summary
The present invention relates to a specialized AI-driven data analytics platform tailored for optimizing engineered T cell therapies in patients, particularly those undergoing treatment for cancer, autoimmune diseases, and inflammatory conditions. Unlike general-purpose AI systems, this platform integrates advanced machine learning, deep learning, and fuzzy logic algorithms to continuously analyze and prioritize real-time data from multiple sources, including patient monitoring systems, laboratory tests, imaging modalities, wearable devices, and genomic profiles. The platform is specifically designed to predict and manage adverse events unique to T cell therapies, such as Cytokine Release Syndrome (CRS) and Tumor Lysis Syndrome (TLS), offering clinicians real-time, personalized guidance that dynamically adjusts treatment protocols during and after T cell infusion. The system's adaptive learning capabilities allow it to evolve by incorporating clinical feedback and patient outcomes, continuously refining its predictive models to enhance precision and effectiveness. By providing robust support for managing complex side effects and delivering actionable recommendations, this invention marks a significant advancement in the application of AI to oncology, offering a highly specialized, innovative approach to enhancing the safety and efficacy of engineered T cell therapies.